Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,782.81
(
2.51%
)
US TECH 100
24,183.06
(
2.72%
)
Dow Jones
47,909.92
(
2.85%
)
Brent Oil
95.13
(
0.31%
)
Bitcoin
71,071.07
(
-0.08%
)
News Focus
News Focus
Post# of 405171
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

PJ007

Send PM Follow Ignore
Followers 27
Posts 3229
Boards Moderated 0
Alias Born 03/20/2019

PJ007

Re: None

Monday, 10/24/2022 9:47:26 AM

Monday, October 24, 2022 9:47:26 AM

Post# of 405171
FUNGAL DISEASES

In pre-clinical studies, Brilacidin has been shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited potent stand-alone efficacy against Cryptococcus neoformans. These data suggest Brilacidin has potential as a novel antifungal agent.

“BRILACIDIN [...] HAS A HIGH LIKELIHOOD OF REACHING COMMERCIALIZATION.”

— Dr. Michael Zasloff

Too Infinity and beyond we go, we are not a DUD and we are not close to being Dunn...we have not even started yet!!!!!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote